Omeros Corporation

Stage 2 · Advancing · week 9

As of Oct 22, 2026, Omeros is in Stage 2, the uptrend phase, now in week 9 (since Aug 20, 2026). It closed at $16.86, 19.9% below its 52-week high and above its 200-day average, which is rising.

$16.86

+3.69% today

$1.2B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is OMER early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S2 14w

S2 15w

S2 18w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 4w → S4 15w → S1 9w → S2 6w → S3 9w → S2 14w → S3 7w → S2 15w → S3 12w → S4 12w → S1 13w → S2 18w → S3 6w → S2 7w → S3 6w → S4 3w → S1 1w → S2 9w current

Total tracked: 165 weeks across 18 stage runs.

OMER among Biotechnology33rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…33	OMEROmeros Corporation	Stage 2 · wk 9	96	−18.7%

vs 52W High

-19.9%

$6.28 lo$21.05 hi

19.9% below 52W high, deeper pullback

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 9

1w13w26w

Week 9, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

26.3%

200 DMA: $13.35 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.41x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-18.7%

+72.2%

+24.7%

YTD

+2.9%

+114.2%

Scan Membership

Breakout Watch

Latest: 2024-11-11

8 appearances in last 60 days. First seen: 2019-05-01.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 9 · Vol 0.41x

2026-10-21S2

Wk 9 · Vol 0.30x

2026-10-20S2

Wk 9 · Vol 0.40x

2026-10-19S2

Wk 9 · Vol 0.76x

2026-10-16S2

Wk 9 · Vol 2.25x

2026-10-15S2

Wk 8 · Vol 0.53x

2026-10-14S2

Wk 8 · Vol 0.51x

2026-10-13S2

Wk 8 · Vol 0.56x

2026-10-12S2

Wk 8 · Vol 0.59x

2026-10-09S2

Wk 8 · Vol 0.44x

2026-10-08S2

Wk 7 · Vol 0.50x

2026-10-07S2

Wk 7 · Vol 0.34x

Moving averages & range

50 DMA

$18.53

200 DMA

$13.35

52W High

$21.05

52W Low

$6.28

5D Low

$16.20

Resistance levels (recent highs)

20d High

$20.08

60d High

$21.05

120d High

$21.05

250d High

$21.05

Next resistance

+19.1%

to 20d High

P/E (TTM)

13.8

Forward 13.7

Dividend Yield

0.00%

P/B -23.7

Omeros: quick answers

What stage is Omeros in?

As of Oct 22, 2026, Omeros (OMER) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 20, 2026 and is in week 9. What the four stages mean

Is Omeros in an uptrend?

Yes. Omeros is in a Stage 2 uptrend. It trades 26.3% above its 200-day average, which is rising.

How far is Omeros from its 52-week high?

Omeros closed at $16.86 on Oct 22, 2026, 19.9% below its 52-week high of $21.05. Its 52-week low is $6.28.

How has Omeros performed over the past year?

As of Oct 22, 2026, Omeros is up 114.2% over the past year and up 2.9% so far in 2026.

Which sector and industry is Omeros in?

Omeros is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.